DelveInsight’s Soft Tissue Sarcoma with Lung Metastases Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Soft Tissue Sarcoma with Lung Metastases, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Soft Tissue Sarcoma with Lung Metastases Market
The market size for Soft Tissue Sarcoma with Lung Metastases in the leading markets is expected to grow significantly by 2036.
The United States accounted for the highest Soft Tissue Sarcoma with Lung Metastases treatment market size in 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
Based on secondary research, STS represents a meaningful oncologic burden, with approximately 14,000 new cases diagnosed annually in the US. Notably, up to 50% of these patients eventually develop lung metastases, highlighting the substantial progression risk and the clinical impact of STS-LM.
Leading soft tissue sarcoma with lung metastases companies, such as Moleculin, Immunophotonics, Philogen, Iovance Biotherapeutics, Chipscreen, Lyvgen, and others, are developing new soft tissue sarcoma with lung metastases treatment drugs that can be available in the soft tissue sarcoma with lung metastases market in the coming years.
The promising soft tissue sarcoma with lung metastases therapies in clinical trials include Annamycin, IP-001, Fibromun, Lifileucel, Chiauranib, LVGN6051, and others.
Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-with-lung-metastases-market
Key Factors Driving the Soft Tissue Sarcoma with Lung Metastases Market
Rising Disease Incidence and Improved Diagnostic Capabilities: Improved imaging technologies, increased disease awareness, and enhanced longitudinal monitoring are helping identify more patients with pulmonary metastatic soft tissue sarcoma. Earlier diagnosis and better recognition of advanced metastatic disease are contributing to treatment demand.
Increasing Demand for Effective Pharmacological Therapies: Pharmacological treatment of STS-LM primarily involves systemic anticancer therapies tailored to disease extent, histology, and prior therapy. Targeted cellular therapies such as TECELRA (afamitresgene autoleucel) are also emerging as precision treatment options for eligible patients.
Growing Preference for Personalized and Multidisciplinary Treatment Approaches: Non-pharmacological treatment approaches such as pulmonary metastasectomy, stereotactic body radiotherapy, and localized ablative techniques are increasingly utilized. Multidisciplinary treatment planning is gaining traction to optimize outcomes in advanced disease settings.
Soft Tissue Sarcoma with Lung Metastases Competitive Landscape
TECELRA (afamitresgene autoleucel) (USWM): Approved genetically modified autologous T-cell therapy for adults with unresectable or metastatic synovial sarcoma with specific HLA-A*02 subtypes whose tumors express MAGE-A4 antigen.
Annamycin (Moleculin Biotech): Investigational next-generation anthracycline designed to overcome multidrug resistance and reduce cardiotoxicity. Currently in Phase I/II development.
IP-001 (Immunophotonics): Investigational intratumoral immunotherapy employing a photothermal mechanism to induce localized tumor cell death and stimulate systemic anti-tumor immune responses. Currently in Phase I/II development.
Discover more about therapies set to grab major Soft Tissue Sarcoma with Lung Metastases market share @ Soft Tissue Sarcoma with Lung Metastases Treatment Landscape
Recent Developments in the Soft Tissue Sarcoma with Lung Metastases Market
In June 2025, Moleculin Biotech reported promising efficacy results for Annamycin from its Phase Ib/II clinical trial in patients with STS-LM.
In August 2024, the US FDA granted accelerated approval to TECELRA (afamitresgene autoleucel) for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy and whose tumors express MAGE-A4 in HLA-A*02 positive patients.
In September 2023, Immunophotonics reported that the first patient was dosed in its multinational clinical trial in France for IP-001.
What is Soft Tissue Sarcoma with Lung Metastases?
Soft Tissue Sarcoma with Lung Metastases represents an advanced stage of soft tissue sarcoma in which malignant tumors of mesenchymal origin have spread to the lungs, reflecting aggressive disease biology, significant tumor burden, and limited therapeutic options. Diagnosis is based on imaging, most commonly chest CT, to identify pulmonary metastases, with histopathologic confirmation when required to verify metastatic sarcoma.
Soft Tissue Sarcoma with Lung Metastases Epidemiology Segmentation
The Soft Tissue Sarcoma with Lung Metastases epidemiology section provides insights into the historical and current patient pool and forecasted trends for the leading markets. The Soft Tissue Sarcoma with Lung Metastases market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Total Incident Cases of Soft Tissue Sarcoma with Lung Metastases
Total Incident Cases of Soft Tissue Sarcoma
Gender-specific Incident Cases of Soft Tissue Sarcoma with Lung Metastases
Country-wise Incident Cases of Soft Tissue Sarcoma with Lung Metastases
Scope of the Soft Tissue Sarcoma with Lung Metastases Market Report
Therapeutic Assessment: Soft Tissue Sarcoma with Lung Metastases current marketed and emerging therapies
Soft Tissue Sarcoma with Lung Metastases Market Dynamics: Key Market Forecast Assumptions of Emerging Soft Tissue Sarcoma with Lung Metastases Drugs and Market Outlook
Key Companies: Moleculin, Immunophotonics, Philogen, Iovance Biotherapeutics, Chipscreen, Lyvgen
Key Therapies: Annamycin, IP-001, Fibromun, Lifileucel, Chiauranib, LVGN6051, TECELRA
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Soft Tissue Sarcoma with Lung Metastases Market Access and Reimbursement
To know more about Soft Tissue Sarcoma with Lung Metastases companies working in the treatment market, visit @ Soft Tissue Sarcoma with Lung Metastases Clinical Trials and Therapeutic Assessment
Table of Contents
Soft Tissue Sarcoma with Lung Metastases Market Report Introduction
Executive Summary for Soft Tissue Sarcoma with Lung Metastases
SWOT Analysis of Soft Tissue Sarcoma with Lung Metastases
Soft Tissue Sarcoma with Lung Metastases Patient Share (%) Overview at a Glance
Soft Tissue Sarcoma with Lung Metastases Market Overview at a Glance
Soft Tissue Sarcoma with Lung Metastases Background and Overview
Soft Tissue Sarcoma with Lung Metastases Epidemiology and Patient Population
Country-Specific Patient Population of Soft Tissue Sarcoma with Lung Metastases
Soft Tissue Sarcoma with Lung Metastases Current Treatment and Medical Practices
Soft Tissue Sarcoma with Lung Metastases Unmet Needs
Soft Tissue Sarcoma with Lung Metastases Emerging Therapies
Soft Tissue Sarcoma with Lung Metastases Market Outlook
Country-Wise Soft Tissue Sarcoma with Lung Metastases Market Analysis (2022–2036)
Soft Tissue Sarcoma with Lung Metastases Market Access and Reimbursement of Therapies
Soft Tissue Sarcoma with Lung Metastases Market Drivers
Soft Tissue Sarcoma with Lung Metastases Market Barriers
Soft Tissue Sarcoma with Lung Metastases Appendix
Soft Tissue Sarcoma with Lung Metastases Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Soft Tissue Sarcoma with Lung Metastases Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapies | DelveInsight
/Apple%20Inc%20logo%20on%20Apple%20store-by%20PhillDanze%20via%20iStock.jpg)
/Visa%20Inc%20gold%20card-by%20hatchpong%20via%20iStock.jpg)